BSE
SUVEN

SUVEN LIFE SCIENCES LTD.

Other
Other

Prices are adjusted according to historical splits.

SUVEN LIFE SCIENCES LTD. Stock Price

Vitals

Today's Low:
₹67.49
Today's High:
₹74.19
Open Price:
₹74.19
52W Low:
₹45.01
52W High:
₹80.5368
Prev. Close:
₹69.8
Volume:
223727

Company Statistics

Market Cap.:
₹7.30 billion
Book Value:
9.199
Revenue TTM:
₹221.31 million
Operating Margin TTM:
-398.05%
Gross Profit TTM:
₹146.83 million
Profit Margin:
0%
Return on Assets TTM:
-7.98%
Return on Equity TTM:
-14.33%

Company Profile

SUVEN LIFE SCIENCES LTD. had its IPO on under the ticker symbol SUVEN.

The company operates in the Other sector and Other industry. SUVEN LIFE SCIENCES LTD. has a staff strength of 0 employees.

Stock update

Shares of SUVEN LIFE SCIENCES LTD. opened at ₹74.19 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹67.49 - ₹74.19, and closed at ₹72.55.

This is a +3.94% increase from the previous day's closing price.

A total volume of 223,727 shares were traded at the close of the day’s session.

In the last one week, shares of SUVEN LIFE SCIENCES LTD. have increased by +10.58%.

SUVEN LIFE SCIENCES LTD.'s Key Ratios

SUVEN LIFE SCIENCES LTD. has a market cap of ₹7.30 billion, indicating a price to book ratio of 24.2315 and a price to sales ratio of 56.0311.

In the last 12-months SUVEN LIFE SCIENCES LTD.’s revenue was ₹221.31 million with a gross profit of ₹146.83 million and an EBITDA of ₹-846648000. The EBITDA ratio measures SUVEN LIFE SCIENCES LTD.'s overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, SUVEN LIFE SCIENCES LTD.’s operating margin was -398.05% while its return on assets stood at -7.98% with a return of equity of -14.33%.

In Q4, SUVEN LIFE SCIENCES LTD.’s quarterly earnings growth was a positive 0% while revenue growth was a negative 96.7%.

SUVEN LIFE SCIENCES LTD.’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at ₹-5.85 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into SUVEN LIFE SCIENCES LTD.’s profitability.

SUVEN LIFE SCIENCES LTD. stock is trading at a EV to sales ratio of 81.9189 and a EV to EBITDA ratio of -15.4218. Its price to sales ratio in the trailing 12-months stood at 56.0311.

SUVEN LIFE SCIENCES LTD. stock pays annual dividends of ₹2.5 per share, indicating a yield of 4.36% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
₹1.21 billion
Total Liabilities
₹605.69 million
Operating Cash Flow
₹0
Capital Expenditure
₹0
Dividend Payout Ratio
0%

SUVEN LIFE SCIENCES LTD. ended 2024 with ₹1.21 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹1.21 billion while shareholder equity stood at ₹564.72 million.

SUVEN LIFE SCIENCES LTD. ended 2024 with ₹0 in deferred long-term liabilities, ₹605.69 million in other current liabilities, 145382000.00 in common stock, ₹419.34 million in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹167.90 million and cash and short-term investments were ₹621.79 million. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.00.

SUVEN LIFE SCIENCES LTD.’s total current assets stands at ₹802.53 million while long-term investments were ₹0 and short-term investments were ₹451.50 million. Its net receivables were ₹13.39 million compared to accounts payable of ₹36.61 million and inventory worth ₹224000.00.

In 2024, SUVEN LIFE SCIENCES LTD.'s operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, SUVEN LIFE SCIENCES LTD. paid ₹0 in dividends in 2024.

Other key metrics

Current Trading Price
₹72.55
52-Week High
₹80.5368
52-Week Low
₹45.01
Analyst Target Price

SUVEN LIFE SCIENCES LTD. stock is currently trading at ₹72.55 per share. It touched a 52-week high of ₹80.5368 and a 52-week low of ₹80.5368. Analysts tracking the stock have a 12-month average target price of .

Its 50-day moving average was ₹64.56 and 200-day moving average was ₹60.7 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 6352.9% of the company’s stock are held by insiders while 102.4% are held by institutions.

Frequently Asked Questions About SUVEN LIFE SCIENCES LTD.

The stock symbol (also called stock or share ticker) of SUVEN LIFE SCIENCES LTD. is SUVEN

The IPO of SUVEN LIFE SCIENCES LTD. took place on

Similar Industry Stocks (Other)

Last Price
Chg
Chg%
₹35.18
-1.27
-3.48%
₹291.4
-20.9
-6.69%
₹2.46
-0.03
-1.2%
Ellora Trading Ltd (ELLORATRAD)
₹16.74
0
0%
₹1.21
0
0%
₹0.74
-0.03
-3.9%
₹36.1
-3.91
-9.77%
₹446.9
-23.5
-5%
₹124.45
-2.5
-1.97%
Axis Bank Limited (AXISBANK)
₹1000.9
0.5
+0.05%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
₹0.14
0.07
+100%
₹0.12
0.04
+45.29%
₹0.96
0.05
+5.4%
₹1.34
-0.35
-20.71%
Humbl Inc (HMBL)
₹0
0
0%

Top Gainers

Last Price
Chg
Chg%
₹0
0
+172200%
₹0
0
+51200%
₹283
280.03
+9428.62%
₹11.2
10.57
+1667.68%
Latch Inc (LTCHW)
₹0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
₹0.19
-123.15
-99.85%
₹0
-0.11
-99.55%
₹0
-0
-97.96%
₹0
-0.01
-93.94%
₹0.01
-0.06
-92.24%

About

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. It engages in drug discovery and development of new chemical entities (NCE) in central nervous system therapies. The company’s product candidates include SUVN-502, which is in Phase II clinical trials for the treatment of Alzheimer’s disease; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist, which has completed Phase I trials for the treatment of sleep and cognitive disorders; SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist, which has completed Phase I trials for the treatment of major depressive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist, which has completed Phase I trials for the treatment of depressive disorders. It is also developing SUVN-I6107 for the treatment of cognitive disorders, SUVN-M8036 for the treatment of psychiatric disorders, SUVN-D1044 for the treatment of gastrointestinal disorders, P2X7 Antagonist for the treatment of pain and inflammation, M4 PAM for the treatment of Psychosis, and 5-HT1A Partial Agonist for the treatment of resistant depression. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was founded in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

Address

# 8-2-334, SDE Serene Chambers, Hyderabad, India, 500034